BioCardia's Leadership Enhancement
BioCardia, Inc. (NASDAQ: BCDA), a prominent player in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has announced the strategic hiring of Farhan Shahab as Vice President of Quality. This appointment is crucial as the company continues to advance its innovative therapeutic solutions.
Farhan Shahab's Background
With over 25 years of experience in the field, Shahab has held various significant roles focused on quality management and regulatory compliance. His previous tenure at Welldoc—where he served as the Vice President of Quality and Regulatory—highlights his capability to navigate the complexities of product regulations and maintain high-quality standards in healthcare solutions.
Contributions to BioCardia
Shahab's diverse experience encompasses leadership roles at respected institutions such as Intuity Medical and AngioScore. His expertise in quality engineering and regulatory affairs has been pivotal in ensuring compliance in high-stakes environments. He also holds prestigious certifications, including Regulatory Affairs Certified (RAC) and Certified Auditor (Exemplar Global), emphasizing his commitment to excellence in quality management.
Vision for Future Growth
Peter Altman, PhD, CEO of BioCardia, has expressed optimism regarding Shahab's onboarding, stating that his extensive background will provide the company with the tools necessary to enhance quality processes and support the successful commercialization of innovative products. Shahab's role is expected to significantly impact the company's ability to scale its investigational therapies.
About BioCardia, Inc.
Headquartered in Sunnyvale, California, BioCardia stands at the forefront of developing therapies targeted at cardiovascular and pulmonary conditions. The company offers proprietary biotherapeutic platforms, including CardiAMP® and CardiALLO™, with ongoing clinical development of multiple product candidates. The Helix™ delivery system and Morph® vascular navigation technology support these advancements, underlining BioCardia's commitment to quality and innovation.
Media and Investor Relations
For further inquiries, contact Miranda Peto, Investor Relations at BioCardia, via email at mpeto@BioCardia.com or by phone at 650-226-0120. Investor inquiries can also be directed to David McClung, Chief Financial Officer, at investors@BioCardia.com.
Frequently Asked Questions
What role does Farhan Shahab hold at BioCardia?
Farhan Shahab is appointed as the Vice President of Quality, bringing extensive regulatory and quality assurance experience.
What is the focus of BioCardia's therapeutics?
BioCardia focuses on developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases.
What are the key product platforms offered by BioCardia?
BioCardia’s key therapeutic platforms include CardiAMP® for autologous cell therapies and CardiALLO™ for allogeneic therapies.
How does BioCardia ensure quality in its products?
BioCardia employs rigorous quality management systems and regulatory compliance, spearheaded by experienced professionals like Farhan Shahab.
Who can I contact for investor-related inquiries?
Investor-related inquiries should be directed to David McClung, Chief Financial Officer, at investors@BioCardia.com.
